Zealand Pharma — Februar 2024
-
Zealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial results
-
Nordea: We reiterate our Buy rating on Zealand Pharma and raise our DCF-derived target price to DKK 570 (355) owing to our more bullish stance on both petrelintide (amylin analogue in obesity) and survodutide (GLP-1/glucagon analogue in obesity).
-
Tak for update og kommentarer omkring Ironwood.
-
ja enestående!
-
havde dem med fra 100 til 294 tilbage til 74 og op igen - uden at få solgt .
har slået mig selv et par gange med et baseball bat undervejs -,men nu... -
nej tak:)
-
helt fair:) De år samlede vinen støv i kælderen - grådighed/angst samlet i mine historiske fejl der - skål:)
-
og skal nok i kælderen 17:00 og finde en god tør onsdags flaske..
-
tirsdag for h...:)
-
Du har vist tyvstartet ST.
-
Ja blivér småberuset bare ved tanken åbenbart..:)
-
Sving, hvis du vil fortsætte exits filosofiske proportionalitetsbegreb, så skal skal du da snart begynde at bære lidt vin ned i den kælder
-
Shortpositioner på danske aktier. https://oam.finanstilsynet.dk/#!/stats-and-extracts-short-net-positions
-
@hanfrank12 - good point - er på trapperne:)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind